Cellectis (CLLS) Equity Average (2015 - 2026)

Cellectis (CLLS) has 12 years of Equity Average data on file, last reported at $67.9 million in Q1 2026.

• In Q1 2026, Equity Average fell 45.06% year-over-year to $67.9 million; the TTM figure through Mar 2026 stood at $67.9 million (down 45.06% YoY), while the FY2025 annual figure was $103.5 million, down 4.08% from the prior year.
• Equity Average declined to $67.9 million in Q1 2026, from $88.2 million in the prior quarter.
• Across five years, Equity Average topped out at $219.8 million in Q1 2022 and bottomed at $67.9 million in Q1 2026.
• A 5-year average of $121.8 million and a median of $119.6 million in 2024 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2023 — Equity Average tumbled 47.05% — and 2024, when it jumped 61.96%.
• Year by year, Equity Average stood at $135.8 million in 2022, then sank by 40.78% to $80.4 million in 2023, then jumped by 61.96% to $130.2 million in 2024, then plunged by 32.28% to $88.2 million in 2025, then slipped by 22.99% to $67.9 million in 2026.
• The last three Equity Average figures came in at $67.9 million (Q1 2026), $88.2 million (Q4 2025), and $98.8 million (Q3 2025), per Business Quant data.

Peer Comparison